Free Trial

TransMedics Group Q3 2024 Earnings Report

TransMedics Group logo
$61.70 +1.17 (+1.93%)
(As of 12/20/2024 05:51 PM ET)

TransMedics Group EPS Results

Actual EPS
$0.12
Consensus EPS
$0.29
Beat/Miss
Missed by -$0.17
One Year Ago EPS
-$0.12

TransMedics Group Revenue Results

Actual Revenue
$108.76 million
Expected Revenue
$115.00 million
Beat/Miss
Missed by -$6.24 million
YoY Revenue Growth
+63.70%

TransMedics Group Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Is Starlink Set For The Largest IPO In History? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Click here now for the urgent details.

TransMedics Group Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
William Blair Cuts Earnings Estimates for TransMedics Group
Q3 EPS Estimate for TransMedics Group Boosted by Analyst
See More TransMedics Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TransMedics Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransMedics Group and other key companies, straight to your email.

About TransMedics Group

TransMedics Group (NASDAQ:TMDX), a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

View TransMedics Group Profile

More Earnings Resources from MarketBeat

Upcoming Earnings